Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up

Financials Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:24 2024-04-26 am EDT 		5-day change 1st Jan Change
26.68 EUR +0.45% Intraday chart for Galapagos NV -1.84% -27.87%
Apr. 08 Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Mar. 28 Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12,060 5,264 3,227 2,722 2,438 1,758 - -
Enterprise Value (EV) 1 6,305 102.9 -1,450 2,722 -1,237 -1,676 -1,368 -889.7
P/E ratio 74.9 x -17.2 x -31.2 x -12.5 x 11.5 x -27.9 x -20.4 x -11.8 x
Yield - - - - - - - -
Capitalization / Revenue 13.5 x 9.93 x 6.65 x 5.39 x 3.11 x 5.21 x 5.59 x 5.72 x
EV / Revenue 7.04 x 0.19 x -2.99 x 5.39 x -1.58 x -4.97 x -4.35 x -2.89 x
EV / EBITDA 16.5 x -0.64 x 11.1 x -13.5 x - 14.6 x 10.1 x 4.77 x
EV / FCF 1.98 x -0.22 x 2.65 x - 2.91 x 5.49 x 4.28 x 1.8 x
FCF Yield 50.5% -457% 37.8% - 34.4% 18.2% 23.4% 55.6%
Price to Book 4.19 x 1.97 x 1.22 x - - 0.65 x 0.67 x 0.91 x
Nbr of stocks (in thousands) 64,667 65,412 65,553 65,836 65,897 65,897 - -
Reference price 2 186.5 80.48 49.22 41.35 36.99 26.68 26.68 26.68
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 895.6 530.3 484.8 505.3 783.5 337.3 314.4 307.6
EBITDA 1 382.7 -160 -131 -202 - -114.7 -135.7 -186.7
EBIT 1 370.3 -178.6 -165.6 -267.5 129 -119.2 -139.5 -163.2
Operating Margin 41.35% -33.68% -34.15% -52.94% 16.46% -35.35% -44.36% -53.05%
Earnings before Tax (EBT) 1 150.1 -309.8 -123 -215.1 - -33.42 -58.47 -96.03
Net income 1 149.8 -305.4 -103.2 -218 211.7 -43.95 -65.24 -95.07
Net margin 16.73% -57.59% -21.29% -43.14% 27.02% -13.03% -20.75% -30.91%
EPS 2 2.490 -4.690 -1.580 -3.320 3.210 -0.9578 -1.306 -2.269
Free Cash Flow 1 3,186 -469.9 -547.7 - -425.2 -305.2 -319.5 -494.8
FCF margin 355.77% -88.6% -112.97% - -54.27% -90.49% -101.64% -160.88%
FCF Conversion (EBITDA) 832.48% - - - - - - -
FCF Conversion (Net income) 2,126.99% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 64.19 143.4 144 137.7 274 136.2 95.12 178.9 150 120 334.7 82.92 60.66 61.15 59.67 64.63
EBITDA -70.14 15.79 - -44.04 - - -110.8 - - - - - - - - -
EBIT 1 -78.2 10.2 -21.1 -76.4 -97.5 -37.6 -132.5 21.97 -10.69 -30.23 148 -36.44 -34.09 -30.46 -37.36 -11.88
Operating Margin -121.82% 7.11% -14.65% -55.48% -35.58% -27.61% -139.26% 12.28% -7.13% -25.19% 44.21% -43.94% -56.19% -49.81% -62.61% -18.38%
Earnings before Tax (EBT) 1 -64.46 19.09 -11.6 -18.22 - 22.25 -207.6 23.46 18.46 25.73 - -8.613 -5.09 -3.95 -12.63 3.86
Net income 1 -64.6 16.37 -13.3 -19 - 21.5 -207.2 23.21 5.101 25.83 157.6 -8.613 -5.09 -3.95 -12.63 3.86
Net margin -100.63% 11.41% -9.24% -13.8% - 15.79% -217.84% 12.97% 3.4% 21.52% 47.08% -10.39% -8.39% -6.46% -21.17% 5.97%
EPS -0.9900 0.2500 - -0.2900 - 0.3300 -3.160 - 0.0800 0.3900 2.390 - - - - -
Dividend per Share 2 - - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/24/22 5/5/22 8/4/22 8/4/22 11/3/22 2/23/23 5/4/23 8/3/23 11/2/23 2/22/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,755 5,161 4,676 - 3,675 3,434 3,127 2,648
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 3,186 -470 -548 - -425 -305 -320 -495
ROE (net income / shareholders' equity) 16.2% -11% -3.89% - 7.96% -1.36% -1.85% -3.32%
ROA (Net income/ Total Assets) 8.82% -5.18% -1.89% - 4.66% -1.03% -1.95% -5.39%
Assets 1 1,698 5,892 5,455 - 4,546 4,260 3,345 1,763
Book Value Per Share 2 44.50 40.80 40.30 - - 41.30 39.80 29.40
Cash Flow per Share 2 53.40 -6.530 -7.530 - - -2.970 -2.980 -4.330
Capex 1 22.4 42.5 54.2 - 19.3 32.3 37.1 30.2
Capex / Sales 2.5% 8.02% 11.18% - 2.46% 9.58% 11.8% 9.82%
Announcement Date 2/20/20 2/18/21 2/24/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Galapagos NV

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.68 EUR
Average target price
38.43 EUR
Spread / Average Target
+44.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GALAPAGOS NV Stock Galapagos NV
-27.87% 1.88B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. Financials Galapagos NV